[.
]
Content:
Each tablet contains: conjugated estrogens, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg or 5 mg.
Uses:
Moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus. Vulvular and vaginal atrophy. Prevention of osteoporosis.
Contraindications:
Known or suspected pregnancy, including use for missed abortion or as a diagnostic test for pregnancy. Known or suspected cancer of the breast or estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Active or past history of thrombophlebitis, thromboembolic disease, or stroke. Liver dysfunction or disease. Lactation.
Special Concerns:
Estrogens reportedly increase the risk of endometrial carcinoma in postmenopausal women. Use with caution in conditions aggravated by fluid retention, including asthma, epilepsy, migraine, and cardiac or renal dysfunction. Estrogens may cause significant increases in plasma triglycerides that may cause pancreatitis and other complications in clients with familial defects of lipoprotein metabolism.
Side Effects:
See individual drug entries.
Drug Interactions:
See individual drug entries.
How Supplied:
See Content
Dosage
?Tablets
Vasomotor symptoms due to menopause, vulvar and vaginal atrophy, prevention of osteoporosis.
Initial: 0.625 mg/2.5 mg estrogen/medroxyprogesterone per day;
then increase to 0.625/5 mg estrogen/medroxyprogestrone per day.
